Plain-English translation of NCT06601465 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
CONVERGE-HF is testing a medication called to see if it can help people with both heart failure and cognitive impairment (memory or thinking problems). The study will compare people taking alongside their regular heart failure treatments to those receiving standard care alone, measuring changes in brain and heart health, thinking ability, and quality of life over 26 weeks.
Many people with heart failure also experience memory and thinking problems, but current treatments don't specifically address both conditions. This medication works in a unique way that researchers believe may protect blood vessels in both the heart and brain, potentially helping both problems at once.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to either take the new medication or continue with standard heart failure care for 26 weeks. If you receive the medication, you'll start with a low dose taken by mouth once daily with food, and it will gradually increase every 2 weeks until reaching the target dose. You'll have heart and brain imaging scans, blood tests, memory and thinking assessments, and check-ins to monitor how you're doing and track any changes in your symptoms and quality of life.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Canada